A. N. Brest, M.D.; J. H. Moyer III, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The use of enzyme inhibitors in the treatment of hypertension is currently being investigated. Several monoamine oxidase (MAO) inhibitors, including iproniazid and 1-phenyl-2-hydrazine propane, have demonstrated significant antihypertensive abilities. In addition, the hypotensive action of these compounds is further enhanced by the therapeutic addition of the thiazide derivatives. The MAO inhibitor nialamide was used alone and in combination with thiazide derivatives in 40 patients with significant antihypertensive results, and serious toxic or side reactions were not encountered. The mechanism of hypotensive action of the MAO inhibitors appears related, at least in part, to ganglionic blockade. More recently, decarboxylase inhibitors have
Brest AN, Moyer JH. Enzyme Inhibitors in the Treatment of Hypertension.. Ann Intern Med. 1961;54:1032. doi: https://doi.org/10.7326/0003-4819-54-5-1032_1
Download citation file:
Published: Ann Intern Med. 1961;54(5):1032.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use